Filing Flows › Dianthus Therapeutics (DNTH) › Q3 2025 › vs Q3 2024
Dianthus Therapeutics (DNTH) Q3 2025 vs Q3 2024 (year over year)
Dianthus Therapeutics's revenue fell $1.8M (-82%) from $2.2M in Q3 2024 to $396K in Q3 2025.
Dianthus Therapeutics, Q3 2025: revenue $396K (-82% year over year), net loss $36.8M, operating cash flow −$30.6M. The chart draws each line against Q3 2024, the increases inside each band.
Every line
| Line | Q3 2025 | Q3 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $396K | $2.2M | −$1.8M | -82% |
| Other income, net | $3.5M | $4.7M | −$1.2M | -25% |
| Net loss | $36.8M | $25.2M | $11.6M | +46% |
| Costs & expenses | $40.7M | $32.1M | $8.6M | +27% |
| Operating costs | $40.7M | $32.1M | $8.6M | +27% |
| Research & development | $32.5M | $25.5M | $6.9M | +27% |
| General & admin | $8.2M | $6.5M | $1.7M | +26% |
| Operating cash sources | $36.8M | $25.2M | $11.6M | +46% |
| Depreciation | $27K | $25K | $2K | +8% |
| Share-based compensation | $5.8M | $3.8M | $2.0M | +51% |
| Working capital & other | $389K | $42K | $347K | +826% |
| Cash used in operations | $30.6M | $21.3M | $9.3M | +44% |
| Net loss absorbed | $36.8M | $25.2M | $11.6M | +46% |
Questions
How much did Dianthus Therapeutics's revenue grow year over year in Q3 2025?
Dianthus Therapeutics's revenue fell $1.8M (-82%) from $2.2M in Q3 2024 to $396K in Q3 2025.